Xu Ya-chao, Xue Fu-shan, Luo Mao-ping, Yang Quan-yong, Liao Xu, Liu Yi, Zhang Yan-ming
Department of Anesthesiology, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100144, China.
Chin Med J (Engl). 2009 Jul 5;122(13):1507-12.
Awake intubation requires an anesthetic management that provides sufficient patient safety and comfort, adequate intubating conditions, and stable hemodynamics. In this prospective clinical study, our aim was to determine the median effective dose (ED(50)) of remifentanil in combination with midazolam and airway topical anesthesia for awake laryngoscopy and intubation.
Thirty-six female adult patients, scheduled for elective plastic surgery under general anesthesia requiring orotracheal intubation were included in this study. Ten minutes after intravenous administration of midazolam 0.1 mg/kg, patients were assigned to receive remifentanil in bolus, followed by a continuous infusion. The bolus dose and infusion rate of remifentanil were adjusted by a modified Dixon's up-and-down method. Patient's reaction score at laryngoscopy and an Observer's Assessment of Alertness/Sedation Scale (OAA/S) were used to determine whether the remifentanil dosage regimen was accepted. During laryngoscopy, 2% lidocaine was sprayed into the airway to provide the topical anesthesia. ED(50) of remifentanil was calculated by the modified Dixon up-and-down method, and the probit analysis was then used to confirm the results obtained from the modified Dixon's up-and-down method. In the patients who were scored as "accept", patient's OAA/S and reaction scores at different observed points, intubating condition score and patient's tolerance to the endotracheal tube after intubation were evaluated and recorded. Blood pressure and heart rate at different measuring points were also noted.
ED(50) of remifentanil for awake laryngoscopy and intubation obtained by the modified Dixon's up-and-down method was (0.62 +/- 0.02) microg/kg. Using probit analysis, ED(50) and ED(95) of remifentanil were 0.63 microg/kg (95% CI, 0.54 - 0.70) and 0.83 microg/kg (95% CI, 0.73 - 2.59), respectively. Nineteen patients who were scored as "accept" had an OAA/S of > 15 and tolerated well laryngoscopy without significant discomfort or gagging. The mean intubating condition score was 1.8 +/- 0.8. The endotracheal tube was well tolerated. During awake laryngoscopy and intubation, blood pressure and heart rate were also kept stable. The postoperative follow up showed that no patient recalled discomfort and pain for airway manipulation.
When combined with midazolam 0.1 mg/kg and airway topical anesthesia, ED(50) of remifentanil for successful awake laryngoscopy and intubation is 0.62 microg/kg in bolus followed by continuous infusion of 0.062 microg*kg(-1)*min(-1). This sedation and analgesia regimen can provide patient safety and comfort, ensure adequate intubating conditions, maintain hemodynamic stability, and prevent negative recall of the airway procedure.
清醒插管需要一种能提供足够患者安全性和舒适度、合适的插管条件以及稳定血流动力学的麻醉管理方法。在这项前瞻性临床研究中,我们的目的是确定瑞芬太尼联合咪达唑仑及气道表面麻醉用于清醒喉镜检查和插管的半数有效剂量(ED50)。
本研究纳入36例计划在全身麻醉下行择期整形手术且需要经口气管插管的成年女性患者。静脉注射0.1 mg/kg咪达唑仑10分钟后,患者被分配接受瑞芬太尼推注,随后持续输注。瑞芬太尼的推注剂量和输注速率采用改良的Dixon上下法进行调整。使用患者喉镜检查时的反应评分和观察者警觉/镇静评分(OAA/S)来确定瑞芬太尼剂量方案是否被接受。在喉镜检查期间,将2%利多卡因喷入气道以提供表面麻醉。瑞芬太尼的ED50通过改良的Dixon上下法计算,然后使用概率分析来确认从改良的Dixon上下法获得的结果。对评分为“接受”的患者,评估并记录不同观察点的患者OAA/S和反应评分、插管条件评分以及插管后患者对气管导管的耐受性。还记录不同测量点的血压和心率。
采用改良的Dixon上下法获得的瑞芬太尼用于清醒喉镜检查和插管的ED50为(0.62±0.02)μg/kg。使用概率分析,瑞芬太尼的ED50和ED95分别为0.63 μg/kg(95%CI,0.54 - 0.70)和0.83 μg/kg(95%CI,0.73 - 2.59)。19例评分为“接受”的患者OAA/S大于15,对喉镜检查耐受性良好,无明显不适或恶心。平均插管条件评分为1.8±0.8。气管导管耐受性良好。在清醒喉镜检查和插管期间,血压和心率也保持稳定。术后随访显示,无患者回忆起气道操作的不适和疼痛。
当与0.1 mg/kg咪达唑仑及气道表面麻醉联合使用时,瑞芬太尼用于成功清醒喉镜检查和插管的ED50为推注0.62 μg/kg,随后以0.062 μg·kg-1·min-1持续输注。这种镇静和镇痛方案可提供患者安全性和舒适度,确保合适的插管条件,维持血流动力学稳定,并防止对气道操作的不良回忆。